Arog’s Phase III trial of crenolanib met its primary endpoint and improved OS and EFS in patients with NPM1/FLT3 co‑mutated ...

CLN-049’s anti-leukaemic impact was observed regardless of FLT3 status, which is the most commonly mutated protein in AML.

The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Innovative research has helped doctors learn more about how cancer cells grow and why it’s a bit different in every person. This has led to the development of drugs that target specific molecules that ...

Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland. The ...

Recurrent driver mutations in FMS-related receptor tyrosine kinase 3 (FLT3) occur in around one-third of patients with de novo acute myeloid leukemia (AML). Although most FLT3 mutations are secondary ...

Guidelines recommend older adults with newly diagnosed AML should be offered antileukemic therapy over best supportive care.

– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...

Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and tolerability ...